Financial Communications Schedule for the First Half of 2017
Press Release – For immediate release – January 26, 2017 – 17:45 CET – Sophia Antipolis, France
Median Technologies (ALMDT.PA), the Imaging Phenomics™ Company, announces the publication date for its 2016 results:
| Publication | Date |
| 2016 Results | April 12, 2017* |
*Distribution after the close of trading
About Median Technologies
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017. Median Technologies has been awarded the 2017 Tech 40 Label and has joined the EnterNext Tech 40 Index. Median is a member of the Bpifrance Excellence Network. More information: www.mediantechnologies.com
Contacts
MEDIAN Technologies
Fredrik Brag
CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com
Actifin (Investors)
Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr
Alizé RP (Press)
Caroline Carmagnol
Wendy Rigal
+33 1 44 54 36 66
median@alizerp.com